Ladies and gentlemen, welcome to the Evonik Industries AG Q4 2023 earnings conference call. I'm Moritz, the conference call operator. I would like to remind you that all participants will be in a listen-only mode, and the conference is being recorded. The presentation will be followed by a question-and-answer session. You can register for questions at any time by pressing star and one on your telephone. For operator assistance, please press star and zero. The conference must not be recorded for publication or broadcast. At this time, it's my pleasure to hand over to Christian Kullmann, CEO. Please go ahead. Thanks a lot, and welcome, and thanks for joining us today. Ladies and gentlemen, 2023 is now finally behind us, and there are no two opinions. The last year was just one. But we fought the challenges and finally delivered on our, what we have to admit, revised targets. And there is no beating around the bush, 2024 will be another test of our persistence, test of our perseverance. For the start into the year, although there are some flaring lights at the end of a very long tunnel, our end markets do not show any broad-based recovery, and the geopolitical landscape remains unchanged and difficult. But first, let's start with a brief summary of what has happened last year. In this uncertain environment, setting priorities is essential, and our priorities were and are crystal clear. We focus on costs and cash. We delivered EUR 250 million savings via our contingency program. We have proven our CapEx discipline and achieved a record high cash conversion. Ladies and gentlemen, we maintain these priorities also in 2024, and actually reinforce our measures. More on that later. We continue to focus our portfolio on businesses with stronger resilience and higher returns. Fair to say, that the last round of the negotiations have taken a bit longer, but finally, today, we signed the sale of our Superabsorbents business. This is the second deal in the divestment process of Performance Materials. Superabsorbents business has generated an average EBITDA of EUR 20 million over the last five years. With a purchase price in the low triple-digit millions EUR, this results in a multiple of around 7 times, which is quite fair in the current environment. With this deal behind us, we can now move ahead with the next steps of our portfolio transformation. The future, ladies and gentlemen, of our portfolio, lies in innovation and sustainability. I'm pleased to report that our six innovation growth fields grew by almost 10% in the last year. A quite remarkable achievement in the current environment. Let me just state one example. Once more, our Gas Filtration Membranes had a really good year, and the growth potential is immense. That is why we are currently investing in a further capacity expansion in Austria. Sustainability is the other key driver of our growth. In 2030, the sales share from Next-Generation Solutions will be over 50%, and in 2023, we are already at 43%. For our footprint, the green electrification of our production is an important lever. Two new PPAs with Vattenfall and RWE are additional steps on this path. After this short introduction, Maike will now give you some more details about our financials. Thank you, Christian, and good afternoon from me as well. With EUR 1.7 billion of EBITDA, we finished the year quite in the middle of our revised guidance range. Despite EUR 30 million headwinds from the Argentinian peso, as well as EUR 20 million inventory devaluations in performance materials in Q4, this was only possible with the significant support of our contingency program. The thousands of smaller measures have overcompensated cost inflation so that our fixed costs in 2023 were clearly above the prior year level. We are expanding these measures into 2024, but as you know, they are only short, short-term in nature and were introduced to fight last year's headwinds as swiftly as possible. It was always clear to us that we also have to work on our cost substructures. We started the reorganization program, Evonik Tailor Made, middle of last year, and have now completed the first phase of the program. We have defined the target organization structure for the whole company, which is to be established by the end of 2026. The overarching idea behind this structure can be summarized in two sentences: by shifting responsibilities from corporate or division level, the operating businesses or business lines will be the future nucleus of Evonik. Through the reduction of hierarchy levels and management spans, we are empowering each of our employees and call for faster decision-making. Tailor Made will change our structures more than any other program before. It's not just about administration, it's a comprehensive reorganization of our group structures and organizational principles. There is still a lot of work ahead of us, but with the completion of the first phase of the program, we can today communicate the savings potential of EUR 400 million by the end of 2026. Up to 2,000 jobs are to be cut worldwide, and this includes a relatively higher share of more expensive management positions. To give you some figures here, Evonik currently has around 4,500 manager positions worldwide, of which up to 1,500 will be eliminated by the end of 2026. Some of the managers will be set free without replacement, while others will be retained but will lose their management roles. Over the next 3 years, we will now implement the target structures across the whole company, all regions, and every unit of the organization. During this process, we will keep you updated as usual. Over the next 3 years, starting already this year, the program will not only support our earnings, but also help to extend our strong track record of cash generation. Despite the pandemic, massive disruptions in global supply chains, and pronounced destocking by our customers, we have achieved an average cash conversion of 40% over the last 5 years, and a cash flow of above EUR 700 million each single year. Needless to say, that this covered our attractive dividend in each of the last 5 years. You can be sure, 5 years of track record is not enough for us, neither for me nor for Chris. Oh, Maike, you can be really sure of that. And that, ladies and gentlemen, brings us to our outlook for the current year. You know it, we know it. There's not much macro tailwind to be expected for the year, so we will take a realistic, conservative approach and assume no change of the currently weak environment for all four quarters ahead of us. However, for Evonik specifically, 2024 will be supported by two factors. Firstly, our self-helping measures. The contingency measures extended into 2024, the operational efficiency measures, like in Animal Nutrition, and the first smaller savings from our new Tailor Made program. Secondly, our Animal Nutrition business, where prices are currently on the rise, relatively independent of the macro environment. And on top, we expect some smaller support from our energy costs and a more material support from lower logistics costs. Overall, these factors give us confidence to grow earnings without much macro support. We are targeting an adjusted EBITDA between EUR 1.7 billion and EUR 2 billion. Based on the just described macro assumptions, this will be mainly driven by our Nutrition and Care division. Apart from the healthy price level in methionine during at least the first half of the year, also Care Solutions with their sustainable specialties and the startup of our biosurfactants plant will contribute to this growth. The first quarter should already support our growth ambition for the year. Although Smart Materials and Performance Materials are expected to remain below their still stronger last year level, a year-on-year stable Specialty Additives, and especially Nutrition and Care, will result in the first quarter clearly above prior year's level. Maike already set the target for the free cash flow. Another year of 40% cash conversion is our ambition level. Ladies and gentlemen, so let me summarize with the last slide. Short term, we'll execute on cash and costs. Midterm, we continue to drive our portfolio transformation to invest into innovation and sustainability, and we're just about to radically reorganize our structures. So from that point of view, what is in for you as an investor? You get a company which is well-positioned as an enabler of sustainable change, with a proven track record of cash generation also during difficult times, with an attractive and reliable dividend, with targeted earnings growth for 2024, and with a lot of self, self-help support over the next three years. With that, thank you for your interest and your time so far, and now we are ready and happy to take your questions. Operator, please, could you take over for the first question in the line? My apologies. I think I was muted. So, we will now begin the question-and-answer session. Anyone who wishes to ask a question may press star and one on their touchtone telephone. You will hear a tone to confirm that you have entered the queue. If you wish to remove yourself from the question queue, you may press star and two. Questioners on the phone are requested to use only handsets while asking a question. Anyone who has a question may press star followed by one at this time. One moment for the first question, please. And the first question comes from Gunther Zechmann from Bernstein. Please go ahead. Morning, everyone, or good afternoon. Thanks for taking my questions. If I can start with the guidance, please, first on the full year and then on Q1. Could you just give us the sensitivities, what's baked in at the higher end, at the lower end of the guidance range? And are your comments about not assuming any macro recovery to be taken at the midpoint, and is that or something else, the main swing factor? And then for Q1, thanks for providing guidance there. Yeah, is it EUR 460 million EBITDA reasonable? The reason I'm asking this is, if you don't guide for a back end loaded 2024, which I think you don't, then to get towards the midpoint of the guidance, assuming normal seasonality, that's the level you would assume you get to. Given we're already in March, I would hope you have some very good visibility on Q1 numbers already. And if I can sneak a last one in, hopefully short, for Maike. The cost savings that you announced today, can you just confirm that it's fully incremental to the existing, cost saving programs? And could you give us a cumulative, net savings number for this year, please? Thank you. Thank you very much, Gunther, for the three questions. And I'm afraid, Maike, they're all for you. Start the call. So the first one on the sensitivity of the guidance of the upper, lower end of the range. The second one, more specifically, what we expect in Q1. And the third one on incremental cost savings and the potential net effect. All right. Yeah, Gunther, good afternoon. I have to concentrate as well to say not good morning, because we are so close to the mornings. So good afternoon from my side as well. You asked regarding upper and lower end of guidance range. Let's start with that one. So the upper end, obviously, we will reach the upper end if the macro recovery is faster than expected, and/or the healthy methionine price level stays also in the second half year. The lower end, obviously, it's quite the contrary, so if you see even further macro deterioration from the current low levels. Then you have said Q1 guidance. What we say, and we can guide you today, is you have mentioned a very clear figure. So what I can tell you today is that it will be clearly above last year's level. Last year was 410, so I can kind of keep it to you to elaborate more on what is clearly above 410, above last year's level. And then you asked about the cost savings, if they are fully incremental or cumulative, or what would be the cumulative, gosh, net savings number. So the savings, what we mentioned, is a EUR 250 million contingencies. They will be basically rolled over from 2023 - 2024. Then we will see an additional EUR 60 million, roughly from Janus, our cost project, our commoditization project of Animal Nutrition. We have shown roughly EUR 50 million in 2023, and we expect another EUR 60 million now in 2024. And then we see we expect first few savings from Evonik Tailor Made from ETM. I hope that answers all your questions. Very helpful. Thank you. The next question comes from Jonathan Chung, from Morgan Stanley. Please go ahead. Hi, thank you. I've got two, please. First one on the cost, the EUR 400 million cost program. I noted that the majority of the staff reduction will be made in Germany. So is it fair to say that Germany that you see now is no longer competitive versus the global chemical productions? And in your views, what is necessary to bring Germany back on their feet and be competitive again? Or is Evonik going to inch its production away from Germany and Europe in the medium term? And on my second question, on methionine. On the slide, you mentioned a methionine contract price is on a healthy level, at least during half one. Can you tell us how you define a healthy level in the context of a year-on-year comparison? If I recall correctly, NHU is bringing a good 150 KT of methionine later this year. How disciplined are your competitors when they bring up new capacity to the market? Do you see a risk to the contract price for the latter half of this year? Thank you. Thank you very much, Jonathan. On your two questions, first one on Germany and the competitiveness of Germany, obviously, that goes to Christian. And the second one, Maike will try to define healthy in terms of the methionine pricing. Hi, Jonathan, Christian here. I have a different view on this because over the course of the last years, Evonik Industries, all over the world, in respect of our administration areas, has really become too complex and too bureaucratic and too hierarchical, let me say, oriented. And that is what we have to now to resolve by getting rid of the structures to become more efficient, more effective, become leaner, and even quicker and faster in acting. Which means, first of all, that we will reduce the level of hierarchies from 10 - 6, and second, that we brought the span of direction foreign executive, the average, span from 1- 3 to 1 - 7 employees. That might become very helpful for us, and that will translate into the cost reduction of roughly EUR 400 million, or give or take EUR 400 million. It might be even a little bit more, let's see. But that has nothing to do with Germany. The reason why we are focusing those cost-cutting and restructuring measures on Germany is still that we're a European company, headquartered in Germany, and the most administrative, let me say, employees are located here, and that is the reason why we do focus on Germany. Besides, you know, Europe, the United States of America and Asia, they do all have advantages, and they do all have, let me say, some concerns. So it is not to say that America and Asia are the exclusive growth regions. It is a mixture, as always. It's a mostly picture of growth and mostly picture of challenges, and contributing to this means we have to become more international, and that is what we are also striving to do. So that is my idea about your first question, and now I hand over to Maike. Yeah. Thank you, Christian, and hello, Jonathan. So you ask about the methionine prices and the demand and supply. Let me see if I can shed some light here. So maybe starting with demand, supply, this is the underlying question you mentioned, is that the volumes. We expect the volumes still with a solid growth throughout 2024. So the market is intact. And so from a supply perspective, this is what drives now the prices. In Q1 and Q2, we see that the market remains tight. Public sources tell us, and now we can tell you, that Adisseo is having production issues in Europe in Q1, then CJ has another shutdown in Malaysia in Q2. Last but not least, also, Evonik is having a shutdown in Q2 due to the expansion projects. For example, our Simex project in Singapore. So that's why we see a clear step-up in contract prices in Q1 and, further, further step-up in Q2. Then H2 depends, obviously, on how, when, and how fast the additional capacity, capacities will come to the market. We all know that NHU has planned additional availability in Q2. We have taken a very bullish price assumption for H2 as a basis for the group guidance. So looking at the overall supply picture for 2024, we feel that the additional 150 KT of the NHU capacity should be offset by the market growth and capacity reductions. So, 770 KT is market growth, and we have the closure of the Adisseo Plant in France. That's an additional 70 KT. Sumitomo is reducing the capacity in two steps. That's an additional 50 KT-70 KT, and CJ, with a 760 KT reduction in Malaysia, will also play into that direction. I hope that helps. Thank you, Maike. Can I just clarify? Did you say you have taken a very bullish assumptions on the methionine price for H2? Exactly. That's what I said. No, no, no. The wording- What? Ah, not a very bullish. Sorry. We have not taken a bullish, sorry. Okay. Thank you for verifying that. Okay, thank you. Thank you. The next question comes from Martin Roediger from Kepler Cheuvreux. Please go ahead. Yes, thank you. First is on the business environment. And here I would like to understand, what do you see in terms of demand for Specialty Additives, Smart Materials, and Performance Materials in Q1? Do you see some signs of restocking, and are you benefiting from some supply chain issues via the Suez Canal, because there are fewer imports of Chinese products to Europe? That's number 1. Number 2, question, slide 4, you talk about the capacity utilization rate. Can you disclose that? What was it for 2023, and how does it compare to 2022? And finally, on energy costs, can you also mention the absolute energy cost bill in 2023, and what was it in 2022? Thank you. Thank you, Martin, for the three questions. The first one on Specialty Additives in Q1. The second one, I didn't 100% get, capacity utilization, in which business or division? Could you help us here, what you meant specifically? It was on slide number 4 of your presentation. I would like to know that on group level, what was the capacity utilization in 2023, and how was it in 2022? Okay. And the third one was on energy costs. I think that was clear, 2022, 2023, and also outlook 2024. I think we can give you. Maike, you want to start with Specialty Additives in Q1, and then Christian can do the capacity utilization and energy costs. We will see once we are there. Okay, I'll start with the business environment and the divisions. Good afternoon, Martin. So maybe let's go through the division by division in Q1. So for Specialty Additives, we see higher volumes year-over-year in all BLs, business lines. Maybe some green shoots in the first weeks of the year, but obviously all come from a very depressed levels. So coatings, the coatings demand is slowly coming back, especially in APAC and here in Europe. The PU Foam and all additives continue to be on a robust level, and we see some restocking benefits which are likely not sustainable. Cross linkers is somewhat weaker than expected because of the higher competitive intensity, and the pricing is slowly coming down, but in line with the lower raw material cost. And then you ask only for? Actually, it was also for Smart Materials. Specialty additives. Say that again, Martin? Sorry, once again. Say it once. Actually, I was also interested in Smart Materials and Performance Materials. If there is any restocking or any benefit from less competition from China because of the supply chain issues, Suez Canal? Yeah, okay, got you. So for Smart Materials and also Nutrition & Care, if you look into the impact of the Red Sea conflict, we mostly produce in the region, for the region, and we see actually that products coming into Europe and products going out of Europe, they have a delay by 10-15 days, sorry. So the supply chain is not disrupted, but it's still, it's simply longer. And so we don't see any big impact on Asian competitors being completely blocked from coming into our European production environment. That counts for Smart Materials and also for Nutrition & Care. Okay. Hi, Martin. I take the other two questions. The first was about the overall utilization rate, and that was around 70%, give or take. Some businesses even below, but as a yardstick, you could take those 70% capacity utilization rate overall, and once again, somewhat different business by business, but that's yardstick for the last year. Then the second question was about the energy costs in 2023. We have hopefully seen the peak by EUR 1.2 billion, and for this year, we do think it is between EUR 1 billion and 1.1 billion. So a slight decline of energy costs is what we do expect for this year in comparison to last year. I guess that are the answers to your questions. Thank you very much. The next question comes from Andreas Heine from Stifel. Please go ahead. Yeah, thanks for taking my questions. I would like to start with the Tailor Made program. So you said the cost savings this year are some, so not too much, and the rest, more or less evenly split between 2025 and 2026, or is a different phasing? Maybe also depending on what the next is, you plan the infrastructure separation. Any thoughts you can share with us how that is progressing? And then lastly, operationally, I'd like to understand a little bit more the Specialty Additives. I look on Q4, your earnings were down 29%, volume was flat, price is down 5%. Going into next year is what you expect, let's say that the volume increase you have elucidated to by business lines is offset by margin pressure, and that's the reason why the earnings are flat, or what is behind the rather cautious view on the earnings progression in Specialty Additives? Thanks. Thank you very much, Andreas. First question on the ETM saving. Maike, if you would take over. Second question, on the process of our Tango project, the separation of technology infrastructure. And then the third one, Specialty Additives, maybe Maike again. Okay. Good afternoon, Andreas. Regarding the cost savings of ETM, let me say that this is probably a little bit too early to say how exactly it will be, the cost savings will be split in 2025 and 2026. We have communicated the program today, and we will start now to discuss in more detail with our works council in the next couple of days and weeks, and also then communicate obviously with our employees to get a better understanding on how that will be split. So bear with me, and we will give you a better understanding on the cost savings and of the split of the cost savings in the course of this year. With that, I hand over to the infrastructure separation to Christian. Hi, Andreas, Christian speaking. About the infrastructure separation, you've asked about the current status of the progress. It is fair to assume that here everything is pretty well on track. So we have spent a lot of time during the first weeks of this year being together with the different teams to discuss how to catch and how to form and forge the infrastructure division, and on the other hand, the technology division. You know, technology is key for us because what is coming out of our innovation departments we're going to ramp up to build up. Therefore, the technology department, our engineers, is key. On the other side, we have the infrastructure department, and here, every idea on how to treat it, how to deal with it, is still lying on the table. So in a nutshell, good progress here within this program, and we will keep you informed if there will be any cutting edge which is of relevant for you, because the timetable you are well aware of means that we will give you, let me say, some more guidance about our ticking, how to deal with this infrastructure in future. Maybe end of the year, first days of last year, to give you somewhat like the next kind of watershed. With this, I hand over to Maike. I will answer your specialty additives question. So basically what we see is a good development in most of the business lines. So I've mentioned already, coatings, PU foams, the lubricant additives, they are all up. The only business line which, where we see headwind is a crosslinkers business line. So we see here an increased competition, and this is why volumes are suffering. I hope that answered your question. Thanks a lot. The next question comes from Chetan Udashi from JP Morgan. Please go ahead. Yeah, hi, thanks. I just wanted to follow up on, Christian, your comment at the beginning of the call where you said, you know, you know, that at least from your perspective, you didn't want to expect any macro recovery this year. Is this just a base, I mean, is this an assumption or is this based on what you actually see so far? Because it feels like in Specialty Additives, there is some improvement in volumes. You talked about methionine, you talked about some growth in your care chemicals part of the business. So I'm just curious, you know, the assumption of no improvement, is that based on just an assumption that you want to take to be conservative? Or is this actually based on what you see in your numbers, especially now in, in your conversations with your, with your key customers? And the second question was, you know, if I'm, if I'm not mistaken, I think the previous indication from, from you was to, to assume a EUR 550 million EBITDA increase every year for the next 4-5 years from the ramp-up of Polyamide 12 Plant. Is that still the case, or has things changed, or have things changed in terms of the timing of the earnings contribution there? Thank you. Thank you, Chetan. I suggest both questions, Christian. You take over the first one on assumption or not on the macro recovery and what we see, and the second one also on the PA 12 market and what we are seeing there in the ramp-up of the new plant. Chetan, do you know what? It is my pleasure to convey the answers to Chetan. H i, Christian speaking. Maybe about your first question. You know me by far, and there you know, that to a certain amount, the ideas I do have means, gut feeling by belly spotting. And if you look at my belly, you know what I have in mind. So, in other words, it is by assumption. As you know, I'm, in this respect, a conservative one, and I'm really keen on to deliver on our promises. So it is by assumption, and the assumption is a conservative one. And as you know, on the other side, the start into the year was, as we have informed you a couple of minutes ago, was a good one. So, we will come out of the first quarter clearly, clearly above, the clearly above the first quarter of last year. So that is about, what I have in mind, what we have in mind about our macroeconomic assumptions. Second, you have asked about, our new capacities, asked about the future of, PA 12. And yes, you do remember it really precisely and very rightly, but you have to be pleased, and I ask you, to contribute to the fact that it is, the question of how macroeconomy is running. So what have we seen here? Or what are we going to see? The demand for our PA 12 is still robust in some segments. Think about coatings, think about electronics. On the other side, it is fair, it is fair to say that even our PA 12 business is somewhat, to certain extent, let me say, a little bit suffering from the sluggish demand outlook into the first half of this year, which is really hopefully colored by more restocking. Now maybe give it some color about the regional picture. What do we see here that might be helpful for you? So I guess fair to assume that in Asia, we do still expect a solid kind of growth, whereas it is in Europe, give or take, flat, and in North America, somewhat below the prior year. So it is here a mixed picture. Maybe to sum it up, the EBITDA contribution we do expect for this year, as mentioned, in some business areas, attractive still. But that goes without saying, depends on the market growth in 2024. So, the better, the higher market growth the recovery would be, the better and higher we would benefit from it. Maybe to close my comment about PA 12, what is definitely a positive is that we do, as of today, do only see very, very, very small volumes from our competitors in the market. And the new capacity of Arkema, they have started to build up in Singapore, is definitely not on stream as of today. So, thinking about PA 12, there are good perspectives if the market recovery would come up. With this, back to Tim, Maike. Okay, that's it. That's it. Sorry. We have answered your questions already. Thanks a lot for your attention so far. Maybe if I can follow up, Christian, on China, post Chinese New Year, any color there? Any interesting developments? What we have seen for the first quarter or what do we see is maybe, give it like this, give it like this. The start, for, for China and for Asia, the start into the year was a good one. Was a good one in respect of sales. In January, it was definitely clearly up, year-over-year, and the order backlog for February was in respect of a year-over-year comparison, running into the same direction, and the same holds true for March. So, giving you a little bit more color, this kind of trend, I'm really cautious. Don't get me wrong, I'm really cautious. It is not sure if it is just restocking or is it somewhat like, you know, the, the early bird of recovery. That is too early to judge upon. So please take the word trend into this direction. So, additives for automotive, for example, and industrial products, coatings and various application, construction, despite, despite the real estate weakness, are doing well. But still, let's see, is it restocking or is it more than restocking? Is it already a recovery, first signs of recovery? That is, what we should judge upon maybe in 4-6 weeks' time. So that's about China and Asia. That's very clear. Thank you very much. And the next question comes from Sebastian Bray from Berenberg. Please go ahead. Hello, everybody. Good afternoon, and thank you for taking my questions. I have three, please. The first is on the nature of contingency cost savings. The business has generated some quite remarkable cash flow over the last two years, and the earnings have held up pretty nicely. If business comes back, does all of the EUR 250 million of contingency cost savings come back in 2025? I I almost have the impression that the near-term EBITDA might be a bit better, but in the long term, it's not possible to stop people traveling for this amount of time and keep these other short-term measures in place without it eventually having an impact. If business returns to normal, do we have a EUR 200 million, EUR 250 million headwind in 2025? My second question is on CapEx. Has anything been delayed? Because Evonik has undershot consensus CapEx expectations for some time now, and I wonder in particular if the methyl mercaptan expansion planned originally for second half of 2024 is coming online as was originally foreseen. My last question is simply on M&A. How are you feeling about divesting the rest of performance materials? Is this really something for 2024 or more likely in 2025? Thank you. Thank you very much, Sebastian, on the three questions. First one, on the contingencies, going forward, goes to Christian, I guess. Second one, CapEx and delays and cuts to Maike. And the third one on M&A, to Christian. Yeah, hi. Let's start with the third one. In respect of the disposal candidate, performance intermediates, C4 value chain, we are prepared, but I guess it would not be prudent to start the concrete process in 2024 because of the weak economic environment. Maybe it is good example to remind you to think about the MMA and PMMA deal we have done a couple of years ago, where we have taken our time to wait for the perfect moment, and the same holds true thinking about the C4 value chain. As of today, I do not think in this year it might be prudent. Therefore it is worthwhile to mention that we are in a position where it is no need to have anything to have anything than a fire sale or somewhat like this. We are strong and robust to take our time, because the Superabsorbents business is an attractive one, and here we do expect a good price, even the best price. Now it is about your first question, cash flow. Yes, some costs will come back. That is a fair assumption of yours. But on the other side, you should keep in mind that by canceling open positions, that by quitting on the refilling of open positions forever, and that by tackling some additional, baskets, to put some money out, to cut budgets, I guess it is fair to assume that these EUR 250 million will, despite how the economic development over the course of the year, will move ahead, that these EUR 250 million, are somewhat like graven into stone. With this, I hand over to Maike. Yes, Sebastian, I'm happy to answer your CapEx questions. So you mentioned, for example, Methyl mercaptan factory in, or plant in, the U.S., and I can reassure you that in the second half of 2024, we will finish our backward integration for the methionine production in Mobile. And that will bring us back to the cost leadership in North America. And we will also finalize our capacity extension for methionine in Singapore with the technology modifications we have mentioned before. So there are of course, we have some, we have wiggled a little bit with some of the CapEx investments. However, our major plants, our major investments, like in membranes, aluminum oxide in Japan, the lipid production in the U.S., are totally in time and in budget. Thank you for taking my questions. Today's last question comes from Jaideep Pandya, from On Field Research. Please go ahead. Thanks a lot. First, this is on methionine. Could you tell us these days what is really the big markets versus the liquid markets? I see clearly a trend in China of increase in liquid share, and I guess NHU's next project is liquid. So how do you see yourself competitively positioned in the powder versus liquid debate? That's my first question. The second one, you know, coming back sort of to what Jaideep was asking PA 12. Now, if you're seeing competitive behavior in cross linkers, which used to be a very you know technology-oriented product, why would we not see this in PA 12 when one ramps up properly? Also curious to know what is your share, especially in the auto market, with the EV players in China, for PA 12, versus some of the more traditional OEMs? Thanks a lot. Thank you, Jaideep, for the two questions. First one, I think both go to Christian. The first one on methionine, liquid, where the powder market share, and the second one, rather specific one on PA 12, I think we partly answered. And let's see how specific we can be on the specific market share in China in PA 12. Hi, I guess, the question about methionine and some changes in the methionine market in respect of, is there a difference between liquid and powder? Here it is fair, really fair to say that the share between liquid and powder over the course of the last years had not changed at all. And, having said so, from the Evonik position, as you know, we are fans and are favorites of the powder, and that is still a better product to feed chicken than each and every single of the rest. And then it was about PA 12, and I guess that one goes to Tim. As you like. I think the question was how, what the position in PA 12 will be going forward, with the entry also of competition, and then a more specific question on the, on our share in the Chinese auto market in PA 12, I guess. Yeah. First of all, it is to say that, in respect of our PA 12, we are really prominent positioned in the automotive market, and I guess we will benefit from the growth perspectives in the Chinese EV auto market for sure. And as far as we are informed, Wanhua, our honorable Chinese competitor in PA 12, is somewhat struggling with entering the market. So it is, from our perspective, as far as we are informed, they are not in. And if only with very tiny amounts of, let me say, so here we feel pretty well and good positioned. And the other one was about? Any follow-up question here on- No, I guess you answered the question. I guess the only probable follow-up on the timing, and apologies for asking this, but you know, historically, when Adisseo came in the market last time with a big capacity expansion, prices probably went down by 10%-15%. I mean, you know, this time around, we are in a relatively balanced market for all the reasons I guess Maike mentioned. So would you think that even if NHU was to add, I don't know, 100 KT-120 KT, prices will still remain around the EUR 2.5 mark for the second half? Even if, even if, our honorable colleagues from NHU would enter the market over the course of this year by ramping their capacities up to the utmost, even if, it is that the, in respect of the volume growth, it would be a wash. Because, first, Adisseo has announced to close their capacities in France, which means roughly 70 KT would go out of the market. Sumitomo will reduce their capacities in two steps, first, end of last year, next, end of this year. And here, we're talking about an amount of, give or take, 60 KT. And you should not forget that, CJ has reduced the capacity of their plant in Malaysia by roughly 40 KT-50 KT. And if you add all those capacities up, even if, and there is anything else ensure, and even if the 150 KT of methionine from NHU would completely come into the market this year, it is nothing else than a wash. So no additional capacities, no additional capacities of volume this year if you calculate the capacities going out of the market and the other ones entering the market. So in other words, it seems to become offset by market growth and capacity reductions. That is, I guess, a fair assumption. Okay. Thanks a lot. Pleasure. Ladies and gentlemen, that was the last question. I would now like to turn the conference back over to Christian Kullmann for any closing remarks. Yeah, ladies and gentlemen, for the first time, it is up to me to end the close instead of Tim. But don't worry, he's in best shape. Ladies and gentlemen, that is what ends our close today. Take care, and thanks a lot for your attention so far. I hope to meet you soon in person. By having said this, bye-bye. Ladies and gentlemen, the conference is now over. Thank you for choosing Chorus Call, and thank you for participating in the conference. You may now disconnect your lines. Goodbye.